Sumitomo Seika Chemicals (4008) Q3 2026 earnings summary

Executive summary

• Net sales for the nine months ended December 31, 2025, were ¥111,667 million, down 0.9% year-over-year, while operating profit rose 18.7% to ¥10,311 million and ordinary profit increased 9.3% to ¥10,494 million.

• Profit attributable to owners of the parent declined 27.8% to ¥4,984 million due to additional provisions for product mischarge expenses.

• Comprehensive income rose 18.9% year-over-year to ¥8,580 million.

Financial highlights

• Basic earnings per share were ¥380.51, down from ¥520.38 year-over-year.

• Return on equity (ROE) was 5.1% for the period.

• Total assets increased to ¥150,564 million, and net assets rose to ¥99,949 million, with an equity-to-asset ratio of 66.4%.

• Research and development expenses for the period were ¥2,088 million.

Outlook and guidance

• Full-year forecast for FY2025 revised upward: net sales expected at ¥148,000 million (+0.3% YoY), operating profit at ¥15,000 million (+40.0%), ordinary profit at ¥15,000 million (+35.1%), and profit attributable to owners at ¥7,000 million (+17.4%).

• Basic earnings per share forecast at ¥535.73; ROE projected at 7.3%.

• Dividend forecast revised to ¥220 per share for FY2025.